Equity and warrant offering · Biotech

Allyx Therapeutics updates May offering to $27.9 million

An October amendment increased the cumulative amount sold in the neurodegeneration drug developer’s existing offering.

Allyx Therapeutics reported $27,927,729 in cumulative securities sales in an amendment filed on October 21, 2026, updating an equity and warrant offering first disclosed on May 11.

The original notice reported $26,427,730 sold after the first sale on May 4. The amendment adds $1,499,999 to that cumulative total, leaving $2,072,270 unsold against a $29,999,999 target. It reports 33 investors without naming the subscribers.

The New Haven company develops investigational oral therapies intended to protect synapses in neurodegenerative disease. Its lead candidate, ALX-001, is being developed for Alzheimer’s and Parkinson’s disease.

Funding history

Equity and warrant offering · This round$27.9M

Sources

  1. Allyx Therapeutics Form D offering disclosuresec.gov · Oct 21, 2026
  2. allyxthera.com
  3. Allyx original May financing noticesec.gov · May 11, 2026
  4. allyxthera.com